Correlation of circulating omentin-1 with bone mineral density in multiple sclerosis: The crosstalk between bone and adipose tissue

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Assadi, Majid ^a   Salimipour, Hooman ^a   Akbarzadeh, Samad ^a   Nemati, Reza ^a   Jafari, Syed Mojtaba ^a   Bargahi, Afshar ^a   Samani, Zahra ^a   Seyedabadi, Mohammad ^a   Sanjdideh, Zahra ^a   Nabipour, Iraj ^a  

^a BUSHEHR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; OMENTIN 1; OSTEOCALCIN; OSTEOPONTIN; UNCLASSIFIED DRUG; VASPIN; C REACTIVE PROTEIN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; SERINE PROTEINASE INHIBITOR; SERPINA12 PROTEIN, HUMAN;

ADIPOSE TISSUE; ADULT; ARTICLE; BONE; BONE DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FEMUR NECK; HIP; HUMAN; MALE; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; TISSUE INTERACTION; BIOSYNTHESIS; BLOOD; CASE CONTROL STUDY; FEMUR; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; REGRESSION ANALYSIS; RISK;

ADIPOSE TISSUE; ADULT; BONE AND BONES; BONE DENSITY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; FEMUR; GENE EXPRESSION REGULATION; GPI-LINKED PROTEINS; HUMANS; LECTINS; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK; SERPINS;

EID: 80052855236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024240     Document Type: Article

References (49)

1. Trujillo ME, Scherer PE, (2006) Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27: 762-78.
2. Confavreux CB, Levine RL, Karsenty G, (2009) A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 310: 21-9.
3. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, et al. (2000) Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207.
4. Luo XH, Guo LJ, Xie H, Zhou HD, Yuan LQ, et al. (2006) Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21: 1648-56.
5. Schaffler A, Neumeier M, Herfarth H, Furst A, Scholmerich J, et al. (2005) Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochim Biophys Acta 1732: 96-102.
6. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, et al. (2006) Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290: E1253-61.
7. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, et al. (2007) Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655-61.
8. Tan BK, Adya R, Farhatullah S, Lewandowski KC, O'Hare P, et al. (2008) Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome: ex vivo and in vivo regulation of omentin-1 by insulin and glucose. Diabetes 57: 801-8.
9. Moreno-Navarrete JM, Catalan V, Ortega F, Gómez-Ambrosi J, Ricart W, et al. (2010) Circulating omentin concentration increases after weight loss. Nutr Metab (Lond) 7: 27.
10. Wada J, (2008) Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 17: 327-33.
11. Hida K, Wada J, Eguchi J, Zhang H, Baba M, et al. (2005) Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A102: 10610-5.
12. Matarese G, Procaccini C, De Rosa V, (2008) The intricate interface between immune and metabolic regulation: a role for leptin in the pathogenesis of multiple sclerosis? J Leukoc Biol 84: 893-9.
13. Gomez R, Lago F, Gomez-Reino J, Dieguez C, Gualillo O, (2009) Adipokines in the skeleton: influence on cartilage function and joint degenerative diseases. J Mol Endocrinol 43: 11-8.
14. Lago F, Dieguez C, Gomez-Reino J, Gualillo O, (2007) Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 3: 716-24.
15. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A, (2008) Leptin and Inflammation. Curr Immunol Rev 4: 70-9.
16. Batocchi AP, Rotondi M, Caggiula M, Frisullo G, Odoardi F, et al. (2003) Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta. J Neuroimmunol 139: 150-4.
17. Matarese G, Di Giacomo A, Sanna V, Lord GM, Howard JK, et al. (2001) Requirement for leptin in the induction and progression of autoimmune encephalomyelitis. J Immunol 166: 5909-16.
18. Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, et al. (2005) Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc Natl Acad Sci U S A 102: 5150-5.
19. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-7.
20. Kurtzke JF, (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-52.
21. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, et al. (2006) Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 99: 196-208.
22. Magni P, Dozio E, Galliera E, Ruscica M, Corsi MM, (2010) Molecular aspects of adipokine-bone interactions. Curr Mol Med 10: 522-32.
23. Korn T, (2008) Pathophysiology of multiple sclerosis. J Neurol 255 (Suppl 6): 2-6.
24. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS, (2001) Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1055-61.
25. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, et al. (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158: 231-9.
26. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, et al. (2002) Osteopontin-a molecule for all seasons. QJM 95: 3-13.
27. Vogt MH, Lopatinskaya L, Smits M, Polman CH, Nagelkerken L, (2003) Elevated osteopontin levels in active relapsing-remitting multiple sclerosis. Ann Neurol 53: 819-22.
28. Vogt MH, Floris S, Killestein J, Knol DL, Smits M, et al. (2004) Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155: 155-60.
29. Chang IC, Chiang TI, Yeh KT, Lee H, Cheng YW, (2010) Increased serum osteopontin is a risk factor for osteoporosis in menopausal women. Osteoporos Int 21: 1401-9.
30. Vogt MH, ten Kate J, Drent RJ, Polman CH, Hupperts R, (2010) Increased osteopontin plasma levels in multiple sclerosis patients correlate with bone-specific markers. Mult Scler 16: 443-9.
31. Altintas A, Saruhan-Direskeneli G, Benbir G, Demir M, Purisa S, (2009) The role of osteopontin: a shared pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 276: 41-4.
32. Saleem U, Mosley TH Jr, Kullo IJ, (2010) Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol 30: 1474-8.
33. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, et al. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130: 456-69.
34. Shiryaev SA, Savinov AY, Cieplak P, Ratnikov BI, Motamedchaboki K, et al. (2009) Matrix metalloproteinase proteolysis of the myelin basic protein isoforms is a source of immunogenic peptides in autoimmune multiple sclerosis. PLoS One 4: e4952.
35. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K, (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122 (Pt 2): 191-7.
36. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, et al. (1999) Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99: 19-26.
37. Soilu-Hanninen M, Koskinen JO, Laaksonen M, Hanninen A, Lilius EM, et al. (2005) High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 65: 153-5.
38. Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari SM, et al. (2009) Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause 16: 950-5.
39. Ueland T, Yndestad A, Oie E, Florholmen G, Halvorsen B, et al. (2005) Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation 111: 2461-8.
40. Nakashima T, Takayanagi H, (2009) Osteoclasts and the immune system. J Bone Miner Metab 27: 519-29.
41. Kurban S, Akpinar Z, Mehmetoglu I, (2008) Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 14: 431-2.
42. Marrie RA, Cutter G, Tyry T, Vollmer T, (2009) A cross-sectional study of bone health in multiple sclerosis. Neurology 73: 1394-8.
43. Mojtahedi MC, Snook EM, Motl RW, Evans EM, (2008) Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and body composition. J Rehabil Res Dev 45: 851-61.
44. Sioka C, Kyritsis AP, Fotopoulos A, (2009) Multiple sclerosis, osteoporosis, and vitamin D. J Neurol Sci 287: 1-6.
45. Steffensen LH, Mellgren SI, Kampman MT, (2010) Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis. J Neurol 257: 410-8.
46. Ozgocmen S, Bulut S, Ilhan N, Gulkesen A, Ardicoglu O, Ozkan Y, (2005) Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab 23: 309-13.
47. Terzi T, Terzi M, Tander B, Canturk F, Onar M, (2010) Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables. J Clin Neurosci 17: 1260-4.
48. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna JP, Lilius EM, et al. (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79: 152-7.
49. Heshmat R, Mohammad K, Majdzadeh SR, et al. (2008) Vitamin D Deficiency in Iran: A Multi-center Study among Different Urban Areas. Iranian J Publ Health 1: 72-8.